Erlotinib hydrochloride

Erlotinib Hydrochloride is a potent, reversible EGFR tyrosine kinase inhibitor that reduces EGFR autophosphorylation in intact tumor cells with an IC₅₀ of 20 nM. As a quinazolinamine derivative, Erlotinib Hydrochloride competitively inhibits ATP binding at the EGFR kinase domain, blocking downstream signaling pathways involved in tumor cell proliferation and survival. The compound is approved for the treatment of non‑small cell lung cancer and pancreatic cancer, with clinical efficacy demonstrated in patients with EGFR‑mutant tumors. Erlotinib Hydrochloride also exhibits multiple polymorphic forms that vary in solubility, stability, and bioavailability, which are crucial considerations for pharmaceutical formulation development. As a high‑purity reference standard, Erlotinib Hydrochloride is indispensable for analytical method development, impurity profiling, quality control testing, and ANDA filings for generic erlotinib manufacturers. Additionally, Erlotinib Hydrochloride serves as a critical tool compound for studying EGFR signaling, drug resistance mechanisms, and developing next‑generation EGFR‑targeted therapies.

 

 Product Parameters

---

Parameter	Specification
Product Name	Erlotinib Hydrochloride
CAS Number	183319-69-9
Molecular Formula	C₂₂H₂₄ClN₃O₄
Molecular Weight	429.90 g/mol
Appearance	Offwhite to pale yellow solid
Melting Point	223225°C
pKa	5.42 at 25°C
Solubility	DMSO: up to 18 mg/mL with warming
Storage Condition	Inert atmosphere, store in freezer, under −20°C

 

Antitumor Drugs

---

Erlotinib Hydrochloride is a small-molecule reversible inhibitor of the epidermal growth factor receptor tyrosine kinase, primarily indicated for second-or third-line treatment of locally advanced or metastatic non-small cell lung cancer and pancreatic cancer.

 

Mechanism Of Action

---

Erlotinib hydrochloride selectively and reversibly targets the epidermal growth factor receptor tyrosine kinase subtype (EGFR-TK). Its mechanism of action involves competing with substrates intracellularly to inhibit EGFR-TK phosphorylation, thereby blocking tumor cell signaling pathways, suppressing tumor growth, and inducing apoptosis. Clinical studies have demonstrated its inhibitory effects against various tumors, offering advantages over conventional chemotherapeutic agents such as milder adverse reactions, improved safety profiles, and better tolerability.

 

Application 

---

1. Erlotinib Hydrochloride is a small-molecule reversible inhibitor of the epidermal growth factor receptor tyrosine kinase, primarily indicated for second-or third-line treatment of locally advanced or metastatic non-small cell lung cancer and pancreatic cancer.

 

2. HER-1/EGFR tyrosine kinase inhibitors.

 

Contact Us

---

For Erlotinib Hydrochloride with uncompromising quality and full regulatory support, Cosperpharm is your go‑to supplier — contact us now.